RXST logo

RXSIGHT INC

RXSTNASDAQ
πŸ† #3572 by market capEarnings Nov 3 Β· PostUS Equity
$5.05β–² $0.16 (+3.27%)
Market closed Β· at close
πŸ””
Track RXST
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.3%
7dβ–² 0.8%
14dβ–² 12.0%
30dβ–² 2.9%
ytdβ–Ό 51.6%
1yβ–Ό 41.1%
🏦Market Cap
$210M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-13.2%
Declining
πŸ“ŠGross Margin
77.5%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
1.6x
Cheap
Otter Score
76
Strong

Trading Snapshot

Day Range
$4.93 – $5.19
52-Week Range
$4.40 – $13.22
Volume (shares)
99,618
Avg Volume (shares)
β€”
Shares Outstanding
41.6M
Next Earnings
2026-11-03

Fundamentals Snapshot

Annual Revenue
$134M
Last Q Revenue
$34M
P/E Ratio
β€”
P/S Ratio
1.6x
EPS (TTM)
$-1.14
Dividend Yield
β€”
Dilution (1yr)
+2.0%
RXST logo

RXSIGHT INC

RXST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$134Mβ–Ό βˆ’3.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.6%β–² +8.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$48Mβ–² +30.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$19Mβ–Ό βˆ’13.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41.2Mβ–² +2.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9Mβ–² +$4M YoY
StockOtter Β· stockotter.space

About RXSIGHT INC

As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Hold
15 analysts
Strong Buy0
Buy1
Hold9
Sell3
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.